Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Publication year range
1.
Blood ; 91(11): 4028-37, 1998 Jun 01.
Article in English | MEDLINE | ID: mdl-9596646

ABSTRACT

The t(16;21)(q24;q22) translocation is a rare but recurrent chromosomal abnormality associated with therapy-related myeloid malignancies and a variant of the t(8;21) translocation in which the AML1 gene on chromosome 21 is rearranged. Here we report the molecular definition of this chromosomal aberration in four patients. We cloned cDNAs from the leukemic cells of a patient carrying t(16;21) by the reverse transcription polymerase chain reaction using an AML1-specific primer. The structural analysis of the cDNAs showed that AML1 was fused to a novel gene named MTG16 (Myeloid Translocation Gene on chromosome 16) which shows high homology to MTG8 (ETO/CDR) and MTGR1. Northern blot analysis using MTG16 probes mainly detected 4.5 kb and 4.2 kb RNAs, along with several other minor RNAs in various human tissues. As in t(8;21), the t(16;21) breakpoints occurred between the exons 5 and 6 of AML1, and between the exons 1 and 2 or the exons 3 and 4 of MTG16. The two genes are fused in-frame, resulting in the characteristic chimeric transcripts of this translocation. Although the reciprocal chimeric product, MTG16-AML1, was also detected in one of the t(16;21) patients, its protein product was predicted to be truncated. Thus, the AML1-MTG16 gene fusion in t(16;21) leukemia results in the production of a protein that is very similar to the AML1-MTG8 chimeric protein.


Subject(s)
Chromosomes, Human, Pair 16 , Chromosomes, Human, Pair 21 , DNA-Binding Proteins , Myelodysplastic Syndromes/genetics , Oncogene Proteins, Fusion , Recombinant Fusion Proteins/genetics , Transcription Factors/genetics , Translocation, Genetic , Amino Acid Sequence , Base Sequence , Chromosome Mapping , Core Binding Factor Alpha 2 Subunit , Humans , In Situ Hybridization, Fluorescence , Molecular Sequence Data , Neoplasm Proteins/chemistry , Neoplasm Proteins/genetics , Polymerase Chain Reaction , Proto-Oncogene Proteins/chemistry , Proto-Oncogene Proteins/genetics , RUNX1 Translocation Partner 1 Protein , Recombinant Fusion Proteins/chemistry , Transcription Factors/chemistry
2.
Cell Mol Biol Res ; 39(1): 3-12, 1993.
Article in English | MEDLINE | ID: mdl-8287069

ABSTRACT

We have investigated the function of the C-terminal and the third intracellular domains of the ETA receptor by expressing truncated and mutated ETA receptors in COS-7 and CHO cells. All the C-terminal truncated ETA receptors were produced at a similar expression level and were detected in the cell membrane using indirect immunostaining. The sizes of the truncated ETA receptors were decreased in proportion to the molecular mass of the truncated amino acid sequence. When the ligand binding activities were determined for various truncated ETA receptors, it was found that more than eight amino acid residues at the proximal cytoplasmic tail of the ETA receptor were required for ET-1 binding. In addition, the deletion of 16 C-terminal amino acid residues from the third intracellular loop severely decreased the ligand binding activity. It seems that deletion of these cytoplasmic domains of the ETA receptor influences the three-dimensional structure of the ligand binding site located in the extracellular domains. The ETA receptor required more than 13 amino acid residues in the proximity of C-terminal cytoplasmic tail and 10 amino acid residues in the C-terminal region of the third intracellular loop to induce the ET-1 dependent increase in intracellular calcium concentration. Both regions are possibly coupled with G-protein to transmit the ET-1 signal.


Subject(s)
Endothelins/metabolism , Protein Conformation , Receptors, Endothelin/chemistry , Signal Transduction , Amino Acid Sequence , Animals , Binding Sites , CHO Cells , Cell Line , Chlorocebus aethiops , Cricetinae , Cricetulus , DNA, Complementary/genetics , Humans , Ligands , Mammals/genetics , Models, Molecular , Molecular Sequence Data , Protein Binding , Protein Structure, Tertiary , Receptors, Endothelin/genetics , Receptors, Endothelin/metabolism , Recombinant Fusion Proteins/metabolism , Sequence Alignment , Sequence Deletion , Sequence Homology, Amino Acid
3.
Biochem Biophys Res Commun ; 187(3): 1241-8, 1992 Sep 30.
Article in English | MEDLINE | ID: mdl-1417800

ABSTRACT

We have investigated the function of N-terminal and C-terminal domains of the human ETA receptor by expressing truncated mutants in COS-7 cells. Three kinds of ETA receptors truncated in the N-terminal extracellular or C-terminal intracellular domains were produced. Deletion of the entire extracellular N-terminal or intracellular C-terminal domain completely inactivated the ET-1 binding activity. However, the deletion of one half of the N-terminal extracellular domain of the ETA receptor, missing one of two N-linked glycosylation sites, maintained complete binding activity. Specific monoclonal antibodies detected all the truncated ETA receptors in the cell membrane fraction of transfected COS-7 cells. The size of the ETA receptor was heterogeneous due to differential glycosylation and distributed in 48K, 45K and 42K dalton bands in Western blot analysis. These results demonstrated that a part of the N-terminal domain in close proximity to the first transmembrane region is required for the ligand binding activity of the ETA receptor, and the C-terminal domain is perhaps necessary as an anchor for maintenance of the binding site.


Subject(s)
Endothelins/metabolism , Receptors, Endothelin/chemistry , Amino Acid Sequence , Blotting, Western , Cell Membrane , Cloning, Molecular , DNA Mutational Analysis , Fluorescent Antibody Technique , Humans , Molecular Sequence Data , Protein Binding , Receptors, Endothelin/immunology , Receptors, Endothelin/metabolism , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...